PROM1 and metastatic malignant neoplasm in the lymph nodes: Furthermore, clinical studies related CD133 as an efficient prognostic factor correlated with poorer clinical outcomes, manifesting via advanced TNM stage, lesser tumor differentiation and early lymph node metastasis.